Skip to main content

Advertisement

Table 6 Relationship between length of non-steroideal anti-inflammatory drug consumption and breast cancer, according to tumor characteristics

From: Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

Variable Category NSAID No consumption Consumption ≤5y Consumption >5y
Controls/cases (n) Controls/cases (n) OR (95 % CI) Controls/cases (n) OR (95 % CI)
Clinical stage 1–2 NSAID (all) 1171/695 484/281 0.85 (0.69–1.06) 255/123 0.69 (0.52–0.92)
Aspirin 1808/1047 79/44 1.01 (0.65–1.58) 23/8 0.74 (0.31–1.73)
Acetic acid derivatives 1754/1025 113/53 0.79 (0.53–1.17) 43/21 0.73 (0.38–1.42)
Propionic acid derivatives 1351/770 380/234 0.93 (0.73–1.17) 179/95 0.78 (0.57–1.08)
NSAID others 1862/1072 33/24 1.56 (0.82–2.95) 15/3 -
3–4 NSAID (all) 1171/136 484/54 0.85 (0.57–1.27) 255/14 0.46 (0.24–0.88)
Aspirin 1808/192 79/11 1.61 (0.78–3.34) 23/1 -
Acetic acid derivatives 1754/190 113/12 1.08 (0.54–2.17) 43/2 -
Propionic acid derivatives 1351/147 380/45 0.91 (0.59–1.40) 179/12 0.54 (0.27–1.09)
NSAID others 1862/201 33/3 - 15/0 -
Pathology Ductal cancer NSAID (all) 1171/835 484/324 0.74 (0.60–0.91) 255/130 0.60 (0.45–0.79)
Aspirin 1808/1225 79/56 1.09 (0.72–1.66) 23/8 0.60 (0.26–1.41)
Acetic acid derivatives 1754/1204 113/64 0.78 (0.53–1.14) 43/21 0.68 (0.36–1.30)
Propionic acid derivatives 1351/918 380/270 0.81 (0.65–1.02) 179/101 0.68 (0.49–0.94)
NSAID others 1862/1259 33/28 1.42 (0.77–2.67) 15/2  
Non-ductal cancer NSAID (all) 1171/151 484/50 0.78 (0.53–1.15) 255/33 0.90 (0.55–1.48)
Aspirin 1808/228 79/5 0.59 (0.23–1.53) 23/1 -
Acetic acid derivatives 1754/219 113/11 0.92 (0.45–1.87) 43/4 -
Propionic acid derivatives 1351/166 380/40 0.79 (0.51–1.22) 179/28 1.15 (0.67–1.96)
NSAID others 1862/232 33/1 - 15/1 -
Inmunohisto-chemistry Hormone + NSAID (all) 1171/727 484/267 0.74 (0.60–0.92) 256/123 0.69 (0.52–0.92)
Aspirin 1808/1069 79/38 0.85 (0.54–1.36) 23/10 0.79 (0.36–1.75)
Acetic acid derivatives 1754/1044 113/50 0.69 (0.46–1.04) 43/23 0.94 (0.51–1.75)
Propionic acid derivatives 1351/805 380/221 0.82 (0.65–1.04) 179/91 0.76 (0.55–1.05)
NSAID others 1862/1089 33/25 1.62 (0.87–3.01) 15/3 -
HER2 +/Hormone- NSAID (all) 1171/172 484/61 0.70 (0.48–1.01) 255/22 0.49 (0.28–0.87)
Aspirin 1808/244 79/10 0.89 (0.41–1.96) 23/1 -
Acetic acid derivatives 1754/238 113/16 1.02 (0.29–3.60) 43/1 -
Propionic acid derivatives 1351/188 380/47 0.66 (0.43–0.99) 179/20 0.61 (0.33–1.12)
NSAID others 1862/251 33/4 - 15/0 -
Triple negative breast cancer NSAID (all) 1171/94 484/49 0.94 (0.60–1.48) 255/14 0.60 (0.30–1.17)
Aspirin 1808/148 79/9 1.74 (0.78–3.89) 23/0 -
Acetic acid derivatives 1754/144 113/8 0.85 (0.36–2.01) 43/2 -
Propionic acid derivatives 1351/103 380/42 1.04 (0.64–1.68) 179/12 0.68 (0.32–1.43)
NSAID others 1862/154 33/2 - 15/1 -
  1. OR odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI family history of breast cancer, number of deliveries, age at first delivery, menarche age, and menopausal status. CI: confidence interval